For SNP microarray experiments, why do Affymetrix justify the use of pooled HapMap data in order to make copy number and loss of heterozygosity inferences on experimental data that is submitted to them? Ideally, you would submit patient-matched normal/reference samples (for solid tumors for example, this would be blood) to them. However, the alternative to this is that they use 250 samples from HapMap as reference. What is the justification for this?
I understand the cost and time benefits. I was speaking from the purely biological perspective. Does using HapMap invalidate your ability to say whether a particular locus has a loss of heterozygosity? Or are inner workings of the calling algorithms (PennCNV, ASCAT, etc.) on the HapMap controls sufficient to do the biology justice?
unfortunately I can't go that further. in my opinion HapMap data is "just" a useful resource, but if you have cases and controls and you have the time and the money to test both hypothesis, surely it'll be more accurate.